Alkermes

Biotech Alkermes Poised To Swell On Pipeline Wins
Investors.com
Wed, 04/17/13 - 10:44 am
Alkermes
Alkermes Announces Restructuring Plan
Yahoo/Zacks
Fri, 04/12/13 - 09:52 am
restructuring
Alkermes
Alkermes Turns to Profit, Ups View
Yahoo/Zacks
Fri, 02/1/13 - 11:01 am
earnings
Alkermes
Alkermes Aims for Psychiatric Drug That Won’t Pack on the Pounds
Xconomy
Mon, 01/7/13 - 10:38 am
Alkermes
Eli Lilly
schizophrenia
ALKS33
Zyprexa
3 Healthcare Mid Caps With Strong EPS Growth Projections And Analyst Backing
Seeking Alpha
Fri, 07/27/12 - 11:55 am
Vivus
Biomarin
Alkermes
A Busy Week For Bio-Pharma Earnings, Drug Approvals
TheStreet.com
Mon, 07/23/12 - 09:15 am
drug approvals
earnings
Amylin
InterMune
Human Genome Sciences
GSK
Bristol-Myers Squibb
Questcor
BiogenIdec
Alexion
Regeneron
Eli Lilly
Amarin
Horizon Pharma
Celgene
Amgen
Gilead
Alkermes
United Therapeutics
Roche
Sanofi
Merck
AstraZeneca
Salix
Progenics Pharmaceuticals
Pluristem Therapeutics' Answer To Big Pharma's Question: What Do We Do Now?
Seeking Alpha
Wed, 07/18/12 - 12:27 pm
Pluristem Therapeutics
Alkermes
AstraZeneca
Bristol-Myers Squibb
Isis Pharmaceuticals
Eli Lilly
Momenta
Merck
Pfizer
Sanofi
Spectrum Pharmaceuticals
Mid-Cap Biotech Stocks Accumulated By The World's Largest Money Managers
Seeking Alpha
Sun, 07/15/12 - 11:22 am
Alkermes
Medivation
Cubist Pharmaceuticals
Ariad Pharmaceuticals
Questcor Pharmaceuticals
Arena Pharmaceuticals
Seattle Genetics
Incyte
United Therapeutics
Amarin
ONYX Pharmaceuticals
Pharmacyclics
Human Genome Sciences
Theravance
Questcor: Why Analysts Are Improving Its Ratings Now
Seeking Alpha
Thu, 07/12/12 - 10:58 am
Questcor
Alkermes
Arena Pharmaceuticals
Vivus
Orexigen
Pipeline Progress at Alkermes/JNJ
Yahoo/Zacks
Wed, 06/13/12 - 11:48 am
JNJ
Alkermes
Invega Sustenna
Janssen
schizophrenia
Vivus Poised For $5 Jump In 12 Months
Seeking Alpha
Tue, 06/12/12 - 01:11 pm
Vivus
Alkermes
Questcor
Orexigen
Arena Pharmaceuticals
Monday's Bio Pharma Momentum Movers And Buy-Out Speculation List
Seeking Alpha
Mon, 06/11/12 - 11:26 am
Alkermes
Amylin
Arena Pharmaceuticals
GSK
Human Genome Sciences
Obagi Medical Products
Once-Weekly Bydureon Provided Greater Glucose Control, Weight Loss and Lower Risk of Hypoglycemia Compared to Once- or Twice-Daily Levemir® in Type 2 Diabetes
Yahoo/Business Wire
Sat, 06/9/12 - 12:35 pm
type 2 diabetes
diabetes
Bydureon
Amylin
Alkermes
Bydureon Improved A1C, Fasting Glucose, Pulse Pressure and Weight Regardless of Baseline Body Weight in Patients with Type 2 Diabetes
Yahoo/Business Wire
Sat, 06/9/12 - 12:33 pm
Bydureon
type 2 diabetes
Amylin
Alkermes
diabetes
Elan to bank $381 million from sale of Alkermes stock
Pharma Times, UK
Wed, 03/14/12 - 09:45 am
Alkermes
Elan
Opportunity In The Weight Loss Drug Market
Seeking Alpha
Tue, 02/21/12 - 07:19 pm
obesity
Vivus
Qnexa
Abbott Laboratories
Alkermes
GSK
JNJ
Roche
Orexigen
FDA nod fuels Bydureon vs. Victoza bout
Fierce Pharma
Mon, 01/30/12 - 04:00 pm
Victoza
diabetes
Bydureon
FDA
Amylin
Novo Nordisk
Alkermes
Amylin, Alkermes Long-Acting Diabetes Drug Wins FDA Approval on Third Try
Bloomberg
Fri, 01/27/12 - 03:12 pm
Amylin
FDA
Alkermes
diabetes
Bydureon
Sector Snap: Specialty drugs in 2012
BusinessWeek
Sun, 01/8/12 - 12:58 pm
Salix
Cubist Pharmaceuticals
Ironwood Pharmaceuticals
Emergent BioSolutions
Xifaxin
Cubicin
Alkermes
Questcor Pharmaceuticals
Biotech Stock Mailbag: Most Important Events for 2012
TheStreet.com
Fri, 12/23/11 - 08:56 am
Oncothyreon
Keryx
Vical
Aeterna Zentaris
Eli Lilly
JNJ
Elan
Celgene
Pfizer
Gilead
Pharmasset
Threshold Pharmaceuticals
Celldex
Amgen
BioVex
Aveo Pharmaceutical
Amylin
Alkermes
Vertex
Cell Therapeutics
Amarin
ONYX Pharmaceuticals
Vivus

Pages